...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Randomized phase II study of paclitaxel and carboplatin or vinorelbine in advanced non-small cell lung cancer.
【24h】

Randomized phase II study of paclitaxel and carboplatin or vinorelbine in advanced non-small cell lung cancer.

机译：紫杉醇和卡铂或长春瑞滨在晚期非小细胞肺癌中的随机II期研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: A randomized phase II trial was conducted to determine if two non-platinum protocols are able to yield a similar efficacy and toxicity profile as compared to two platinum-based doublets in advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: A total of 61 patients were randomly assigned to a reference regimen of carboplatin and paclitaxel (repeated every 3 weeks) or to one of three experimental regimens: paclitaxel plus vinorelbine (repeated every 3 or 4 weeks) and carboplatin plus paclitaxel (repeated every 4 weeks). RESULTS: The objective remission rate for all the patients was 34.1%. The median progression-free survival for all the patients was 3 months. The median overall survival and one-year overall survival were 6 months and 21.5%, respectively. Toxicity was moderate and manageable. Response, survival and toxicity did not significantly differ between the four treatment groups. CONCLUSION: The efficacy and toxicity profile of platinum-free combinations is comparable to that of platinum-based doublets.
机译：背景：进行了一项随机的II期临床试验，以确定在晚期非小细胞肺癌（NSCLC）中，两种非铂方案是否能够产生与两种基于铂的双重峰相比相似的功效和毒性。病人和方法：总共61例患者被随机分配至卡铂和紫杉醇的参考方案（每3周重复一次）或以下三个实验方案之一：紫杉醇加长春瑞滨（每3或4周重复一次）和卡铂和紫杉醇（每4周重复一次）。结果：所有患者的客观缓解率为34.1％。所有患者的中位无进展生存期为3个月。中位总生存期和一年总生存期分别为6个月和21.5％。毒性适中且易于控制。四个治疗组之间的反应，生存率和毒性无显着差异。结论：无铂组合的功效和毒性与铂基双胶合剂相当。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号